Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity

HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner